In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2

New antiretroviral drugs are needed to treat HIV-2 infected patients failing therapy. Herein, we evaluate the activity of novel reverse transcriptase inhibitors tenofovir alafenamide (TAF) and OBP-601(2,3-didehydro-3-deoxy-4-ethynylthymidine) against primary isolates from HIV-2 infected patients exp...

Full description

Bibliographic Details
Main Author: Bártolo, Inês (author)
Other Authors: Borrego, Pedro (author), Gomes, Perpétua (author), Gonçalves, Fátima (author), Caixas, Umbelina (author), Pinto, Inês V. (author), Taveira, Nuno (author)
Format: article
Language:eng
Published: 2019
Subjects:
HIV-2
Susceptibility to TAF
TDF and OBP-601
Resistance mutations
Online Access:http://hdl.handle.net/10400.26/30647
Country:Portugal
Oai:oai:comum.rcaap.pt:10400.26/30647

Internet

http://hdl.handle.net/10400.26/30647

Similar Items